These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9740345)

  • 1. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial).
    Preisack MB; Bonan R; Meisner C; Eschenfelder V; Karsch KR
    Eur Heart J; 1998 Aug; 19(8):1232-8. PubMed ID: 9740345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
    Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
    J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
    Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
    Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
    N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
    Yusuf S; Mehta SR; Xie C; Ahmed RJ; Xavier D; Pais P; Zhu J; Liu L;
    JAMA; 2005 Jan; 293(4):427-35. PubMed ID: 15671427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
    JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of low dose heparin in elective coronary angioplasty.
    Koch KT; Piek JJ; de Winter RJ; David GK; Mulder K; Tijssen JG; Lie KI
    Heart; 1997 Jun; 77(6):517-22. PubMed ID: 9227294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute closure during coronary excimer laser angioplasty and conventional balloon dilatation: a comparison of management outcome and prediction.
    Preisack MB; Athanasiadis A; Voelker W; Baumbach A; Karsch KR
    Eur Heart J; 1993 Feb; 14(2):195-204. PubMed ID: 8449195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
    Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
    Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Increase in troponin levels after coronary angioplasty (PTCA) in stable angina pectoris].
    Varvarovský I; Brtko M; Branny M
    Vnitr Lek; 2004 Mar; 50(3):203-7. PubMed ID: 15125370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
    Schächinger V; Allert M; Kasper W; Just H; Vach W; Zeiher AM
    Circulation; 1994 Nov; 90(5):2258-66. PubMed ID: 7955182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
    Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Hirulog Angioplasty Study Investigators.
    Piana RN; Ahmed WH; Chaitman B; Ganz P; Kinlay S; Strony J; Adelman B; Bittl JA
    J Am Coll Cardiol; 1999 Jan; 33(1):73-8. PubMed ID: 9935011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
    Gibson CM; Dotani MI; Murphy SA; Marble SJ; Dauterman KW; Michaels AD; Dodge JT;
    Am Heart J; 2002 Jul; 144(1):130-5. PubMed ID: 12094199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of low molecular weight heparin to predict clinical outcome in patients with unstable angina that had undergone percutaneous coronary intervention.
    Hong YJ; Jeong MH; Lee SH; Park OY; Kim JH; Kim W; Rhew JY; Ahn YK; Cho JG; Park JC; Suh SP; Ahn BH; Kim SH; Kang JC
    Korean J Intern Med; 2003 Sep; 18(3):167-73. PubMed ID: 14619386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
    Carswell CI; Plosker GL
    Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.
    Bittl JA; Strony J; Brinker JA; Ahmed WH; Meckel CR; Chaitman BR; Maraganore J; Deutsch E; Adelman B
    N Engl J Med; 1995 Sep; 333(12):764-9. PubMed ID: 7643883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty.
    Wilson JM; Dougherty KG; Ellis KO; Ferguson JJ
    Cathet Cardiovasc Diagn; 1995 Jan; 34(1):1-5. PubMed ID: 7728844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.
    van den Bos AA; Deckers JW; Heyndrickx GR; Laarman GJ; Suryapranata H; Zijlstra F; Close P; Rijnierse JJ; Buller HR; Serruys PW
    Circulation; 1993 Nov; 88(5 Pt 1):2058-66. PubMed ID: 8222099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty. Clinical and procedural predictors. Heparin Registry Investigators.
    Wolfe MW; Roubin GS; Schweiger M; Isner JM; Ferguson JJ; Cannon AD; Cleman M; Cabin H; Leya F; Bonan R
    Circulation; 1995 Aug; 92(3):311-9. PubMed ID: 7634443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.